newsfilter
← Latest News
Business Wire·

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company